Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutritions Ltd manufactures and trades Pharmaceutical, Nutraceutical, Herbal and Ayurvedic commodities[1]
- Market Cap ₹ 41.4 Cr.
- Current Price ₹ 44.1
- High / Low ₹ 53.3 / 37.8
- Stock P/E 24.5
- Book Value ₹ 16.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 11.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 55.2 days to 39.1 days
Cons
- Stock is trading at 2.76 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.07% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 1m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 16.71 | 1.43 | 6.07 | 26.76 | 28.70 | 51.31 | 60.16 | |
| 15.50 | 1.05 | 5.61 | 25.68 | 27.92 | 49.54 | 57.32 | |
| Operating Profit | 1.21 | 0.38 | 0.46 | 1.08 | 0.78 | 1.77 | 2.84 |
| OPM % | 7.24% | 26.57% | 7.58% | 4.04% | 2.72% | 3.45% | 4.72% |
| 0.00 | 0.00 | 0.00 | 0.02 | 0.27 | 0.13 | 0.10 | |
| Interest | 0.73 | 0.05 | 0.18 | 0.48 | 0.34 | 0.21 | 0.10 |
| Depreciation | 0.29 | 0.02 | 0.12 | 0.28 | 0.25 | 0.21 | 0.41 |
| Profit before tax | 0.19 | 0.31 | 0.16 | 0.34 | 0.46 | 1.48 | 2.43 |
| Tax % | 36.84% | 25.81% | 6.25% | -26.47% | 34.78% | 24.32% | 30.45% |
| 0.12 | 0.23 | 0.15 | 0.42 | 0.29 | 1.11 | 1.69 | |
| EPS in Rs | 0.38 | 0.22 | 0.46 | 0.32 | 1.18 | 1.80 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 58% |
| TTM: | 59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 8% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1.93 | 3.00 | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 |
| Reserves | 0.00 | 0.23 | 1.44 | 6.49 | 6.78 | 8.64 | 5.63 |
| 5.55 | 5.88 | 5.46 | 4.38 | 3.21 | 0.32 | 0.00 | |
| 5.69 | 5.44 | 5.45 | 7.95 | 7.33 | 9.84 | 15.90 | |
| Total Liabilities | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 |
| 1.12 | 1.15 | 1.07 | 0.94 | 0.83 | 1.48 | 2.29 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 |
| Investments | 0.00 | 0.00 | 0.06 | 2.93 | 2.84 | 4.70 | 4.70 |
| 12.05 | 13.40 | 14.56 | 19.49 | 18.17 | 17.30 | 23.90 | |
| Total Assets | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -0.76 | 0.40 | 1.38 | -0.32 | 1.09 | 3.13 | 2.71 | |
| -0.66 | 0.00 | -0.70 | -4.58 | 0.46 | -0.88 | -1.23 | |
| 1.07 | -0.24 | -0.06 | 4.27 | -1.52 | -2.18 | -0.42 | |
| Net Cash Flow | -0.35 | 0.17 | 0.62 | -0.63 | 0.03 | 0.07 | 1.06 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 160.55 | 2,141.50 | 430.54 | 124.26 | 111.66 | 71.78 | 102.84 |
| Inventory Days | 130.73 | 1,690.75 | 369.26 | 103.22 | 89.87 | 39.99 | 32.83 |
| Days Payable | 186.46 | 2,156.44 | 434.08 | 130.02 | 99.69 | 67.10 | 93.80 |
| Cash Conversion Cycle | 104.82 | 1,675.81 | 365.73 | 97.45 | 101.84 | 44.67 | 41.87 |
| Working Capital Days | 60.07 | 1,028.64 | 268.79 | 79.79 | 79.99 | 46.31 | 39.13 |
| ROCE % | 3.84% | 6.55% | 5.34% | 11.56% | 17.64% |
Documents
Announcements
-
Trading Window
30 September 2025 - Trading window closed from 1 Oct 2025 until 48 hours after Q2/H1 unaudited results publication.
-
Shareholders meeting
29 September 2025 - Scrutinizer report: AGM on 25 Sep 2025; all 9 resolutions passed; votes in favour 6,474,400 (res 1-5), 496,000 (res 6-9).
-
Shareholders meeting
29 September 2025 - Submitted voting results of AGM held 25 September 2025 via VC/OAVM.
-
Shareholders meeting
25 September 2025 - 5th AGM on 25 Sep 2025: FY2025 financials considered; two directors reappointed; material RPT approvals sought.
-
General Updates
3 September 2025 - Book closure 18–25 Sep 2025; cutoff 3 Sep and 18 Sep 2025 for 5th AGM notices/e-voting.
Business Overview:[1]
Company manufactures and sells Nutraceutical and Herbal dietary supplement formulations, ingredients and research. It manufactures private label brands for different companies and its own brands, selling through online and direct channels. Company is a specialized Contract manufacturer for different formulation in Nutraceuticals and Herbal products